Isomorphic Labs Limited

Isomorphic Labs Limited specializes in harnessing advanced AI technologies to accelerate drug discovery processes, enabling pharmaceutical firms to create effective medicines more efficiently. Isomorphic Labs Limited, founded in 2021 in London, UK, focuses on applying artificial intelligence to transform the drug discovery field. The company has not undergone any major pivots in its strategy since its inception. Isomorphic Labs specializes in utilizing advanced AI technologies to expedite the drug discovery process.

Their core product offerings include predictive and generative AI models designed to analyze complex biological data, thus enabling the design of novel drug molecules and predicting their efficacy. The end use cases focus on addressing various critical health challenges by aiding in the development of innovative medicines aimed at treating severe diseases. These services are particularly aimed at pharmaceutical companies, research institutions, and biotech firms globally, with an emphasis on markets such as North America and Europe. By leveraging insights from their systems, clients can enhance their research capabilities and accelerate the timeline from concept to clinical applications.

The revenue structure of Isomorphic Labs is derived from service agreements and partnerships with pharmaceutical and biotech companies. These transactions involve providing access to their proprietary AI models under subscription agreements, allowing clients to benefit from ongoing use of the technology. Additionally, Isomorphic Labs engages in direct collaborations with organizations to customize solutions for specific drug development projects, which can result in milestone payments based on project advancements. The pricing structure for these services is tailored to meet the individual needs of clients, reflecting the complexity and scope of each engagement, particularly for flagship offerings that highlight the company’s AI capabilities.

In May 2026, Isomorphic Labs Limited raised GBP 1. 6 billion series B funding led by Thrive Capital, with participation from GV, Alphabet, Temasek Holdings, CapitalG, Sovereign AI, and MGX. The company plans to use the May 2026 funding to further develop and deploy its AI drug design engine, advance multiple drug candidates toward clinical trials, and expand hiring across AI, engineering, and drug development teams.